The first medicine has now received general reimbursement under Denmark’s pilot scheme for confidential prices.
Anzupgo cream, used for chronic hand eczema, is the first product approved under the scheme. The general reimbursement applies from 25 May 2026.
What happened
-
LEO Pharma first applied for general reimbursement on standard terms, but the price was assessed as too high versus the treatment value.
-
LEO Pharma then negotiated a confidential price with Amgros, which was approved by the regions.
-
On that basis, the Medicines Reimbursement Committee recommended general reimbursement to the Danish Medicines Agency.
What this means in practice
-
Patients prescribed the medicine will automatically receive reimbursement at the pharmacy.
-
The scheme is open until 30 June 2028.
-
The agency also noted the cream’s mild side effect profile compared with other treatments for chronic hand eczema.
